DeutschNewstral
Article
Financial Times on 2023-10-24 06:22
Novo Nordisk and Eli Lilly hoover up smaller obesity drug groups
Related news
- BRoche Strikes $3.1 Billion Deal for Obesity Drugmaker. It Hopes to Compete with Eli Lilly, Novo Nordisk. 2 min readbarrons.com
Obesity drug shows promise, Eli Lilly saysArkansas Online
Can biotech startups upstage Eli Lilly and Novo Nordisk?The Economist- Eli Lilly & Co: Eli Lilly to seek obesity drug approval that could disrupt weight loss marketFinancial Times
- FEli Lilly & Co: Eli Lilly predicts sales jump from obesity drug demandft.com
- IEli Lilly stock price forecast ahead of obesity drug approvalinvezz.com
- FEli Lilly & Co: Eli Lilly races to boost capacity for rival to Novo Nordisk weight-loss drugft.com
- TNovo Nordisk, Eli Lilly leap as Ozempic show promise in kidney patient treatmentthestreet.com
Novo Nordisk Will Lower Insulin Prices Up To 75%, Following Eli LillyForbes- UInsulin API Market Size Current and Future | Novo Nordisk, Sanofi-Aventis, Eli Lilly, Tonghua Dongbao, Ganleeunlvrebelyell.com
- MPfizer enters weight reduction drug market with Novo Nordisk, Eli Lillymvtelegraph.com
Novo Nordisk plans to cut insulin prices up to 75%, following Eli Lillyocregister.com- BNew Obesity Drugs From Lilly and Novo Nordisk Generate Excitement3 min readbarrons.com
- ROp/Ed: Novo Nordisk, Eli Lilly Must Stop Ripping Off Americans With High Drug Pricesrandomlengthsnews.com
- Eli Lilly achieves hard-won success with Alzheimer’s and obesity drugsFinancial Times
- Pharmaceuticals sector: Approval for Eli Lilly obesity drug sets up rival to WegovyFinancial Times
- DEli Lilly says obesity drugs not for 'cosmetic' use amid digital-sales pushdcourier.com
Eli Lilly starts website to connect patients with new obesity treatment, Zepbound, other drugsSeattle Times- IEli Lilly to expand in obesity drugs with $1.925 billion acquisition of Versanis Bioinvezz.com